Suggestion Performance
21 suggestions in scope
Keep
16
76% of portfolio
Modify
0
0% of portfolio
Retire
3
14% of portfolio
Watch
2
10% of portfolio
Driving dimension impact
What resonates with KEEs
| Dimension | N | Utilization | Avg Fit |
|---|---|---|---|
| Tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | 6 | 100% | 4.2 |
| Belief in treatment to progression in 1L | 5 | 80% | 3.5 |
| QoL vs other regimens | 4 | 75% | 3.8 |
| AE management & prophylaxis | 3 | 33% | 3.5 |
| Patient segmentation | 2 | 50% | 3.0 |
| Importance of early disease control | 1 | 100% | 5.0 |
Material effectiveness
Per Beacon asset
| Asset | Used | Avg Fit | Strong |
|---|---|---|---|
| DESTINY-Breast09 Medical Q&A | 15 | 4.2 | 33% |
| DESTINY-Breast09 | 12 | 4.1 | 25% |
| Discussion Guide: T-DXd+ P in 1L HER2-Positive mBC | 12 | 4.1 | 25% |
| T-DXd ILD/Pneumonitis Medical Reactive Q&A | 2 | 4.5 | 0% |
| Interstitial Lung Disease | 1 | 5.0 | 0% |
All suggestions
Click a row to open KEE detail
Sort by
| Priority | KEE | Next Action | Status | Fit | Outcome | Verdict |
|---|---|---|---|---|---|---|
| Primary | Alvaro Menendez Rivera, MD | Deepen discussion of tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 3 | Neutral / mixed | Keep |
| Primary | Anjali Budhathoki, M.D | Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 5 | Useful | Keep |
| Primary | Julie Huynh, MD | Rebalance perspective on patient segmentation | Not used | 1 | Not useful | Retire |
| Primary | Matthew Ellis, MD PHD | Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 5 | Useful | Keep |
| Primary | Scott Barron, M.D. | Discover current approach to AE management & prophylaxis | Used | 5 | Useful | Keep |
| Primary | Sunil Babu, M.D. | Discover current approach to QoL vs other regimens | Used | 4 | Neutral / mixed | Keep |
| Primary | Wassim Mchayleh, MD | Discover current approach to QoL vs other regimens | Not used | 2 | Not useful | Retire |
| Secondary | Alvaro Menendez Rivera, MD | Rebalance perspective on patient segmentation | Used | 5 | Strongly useful | Keep |
| Secondary | Anjali Budhathoki, M.D | Discover current approach to belief in treatment to progression in 1L | Planned | - | - | Watch |
| Secondary | Julie Huynh, MD | Introduce tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 4 | Useful | Keep |
| Secondary | Matthew Ellis, MD PHD | Discover current approach to QoL vs other regimens | Used | 5 | Strongly useful | Keep |
| Secondary | Scott Barron, M.D. | Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 4 | Useful | Keep |
| Secondary | Sunil Babu, M.D. | Discover current approach to tx selection patterns between T-DXd + P and existing regimens for 1L HER2+ a/mBC | Used | 4 | Strongly useful | Keep |
| Secondary | Wassim Mchayleh, MD | Discover current approach to belief in treatment to progression in 1L | Used | 5 | Strongly useful | Keep |
| Tertiary | Alvaro Menendez Rivera, MD | Discover current approach to QoL vs other regimens | Used | 4 | Strongly useful | Keep |
| Tertiary | Anjali Budhathoki, M.D | Discover current approach to AE management & prophylaxis | Planned | - | - | Watch |
| Tertiary | Julie Huynh, MD | Rebalance perspective on importance of early disease control | Used | 5 | Useful | Keep |
| Tertiary | Matthew Ellis, MD PHD | Discover current approach to belief in treatment to progression in 1L | Used | 3 | Useful | Keep |
| Tertiary | Scott Barron, M.D. | Discover current approach to belief in treatment to progression in 1L | Used | 3 | Neutral / mixed | Keep |
| Tertiary | Sunil Babu, M.D. | Discover current approach to belief in treatment to progression in 1L | Used | 3 | Neutral / mixed | Keep |
| Tertiary | Wassim Mchayleh, MD | Discover current approach to AE management & prophylaxis | Not used | 2 | Not useful | Retire |